Literature DB >> 16513568

The treatment of amblyopia.

Jonathan M Holmes1, Michael X Repka, Raymond T Kraker, Michael P Clarke.   

Abstract

Recent studies suggest that children with amblyopia associated with anisometropia, strabismus, or both should be treated initially with best refractive correction until visual acuity is stable. This may take several months, and a proportion of children will achieve equal visual acuity with glasses alone. For residual anisometropic and strabismic amblyopia, the initial choice of patching or atropine should involve the parent and the child. The dose of prescribed patching or atropine may initially be quite modest, such as 2 hours of patching a day or twice weekly atropine. Treatment should be offered to children until at least 12 years of age and possibly to teenagers. Ongoing studies are addressing the role of undertaking near activities while patched and the role of atropine for severe amblyopia and for older amblyopic children. Future studies are needed to investigate the best treatment strategies for residual amblyopia, whether weaning treatment is needed at the end of a course, and how compliance can be enhanced.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513568     DOI: 10.1080/09273970500536227

Source DB:  PubMed          Journal:  Strabismus        ISSN: 0927-3972


  10 in total

1.  Effectiveness of a Binocular Video Game vs Placebo Video Game for Improving Visual Functions in Older Children, Teenagers, and Adults With Amblyopia: A Randomized Clinical Trial.

Authors:  Tina Y Gao; Cindy X Guo; Raiju J Babu; Joanna M Black; William R Bobier; Arijit Chakraborty; Shuan Dai; Robert F Hess; Michelle Jenkins; Yannan Jiang; Lisa S Kearns; Lionel Kowal; Carly S Y Lam; Peter C K Pang; Varsha Parag; Roberto Pieri; Rajkumar Nallour Raveendren; Jayshree South; Sandra Elfride Staffieri; Angela Wadham; Natalie Walker; Benjamin Thompson
Journal:  JAMA Ophthalmol       Date:  2018-02-01       Impact factor: 7.389

2.  A morphological study of amblyopic eyes in children failing to achieve normal visual acuity after electronically monitored long-term occlusion treatment.

Authors:  Claudia Kuhli-Hattenbach; Michael Janusz Koss; Thomas Kohnen; Maria Fronius
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-23       Impact factor: 3.117

3.  Outcome of conventional treatment for adult amblyopia.

Authors:  Fumiko Kishimoto; Chiaki Fujii; Yoshie Shira; Kayoko Hasebe; Ichiro Hamasaki; Hiroshi Ohtsuki
Journal:  Jpn J Ophthalmol       Date:  2013-10-26       Impact factor: 2.447

Review 4.  Amblyopia: a mini review of the literature.

Authors:  Evgenia Kanonidou
Journal:  Int Ophthalmol       Date:  2011-03-20       Impact factor: 2.031

5.  P-VEP as predictor of occlusion therapy.

Authors:  Satendra Singh; Shikha Gautam
Journal:  Korean J Ophthalmol       Date:  2009-06-09

Review 6.  Amblyopia and binocular vision.

Authors:  Eileen E Birch
Journal:  Prog Retin Eye Res       Date:  2012-11-29       Impact factor: 21.198

Review 7.  The relationship between anisometropia and amblyopia.

Authors:  Brendan T Barrett; Arthur Bradley; T Rowan Candy
Journal:  Prog Retin Eye Res       Date:  2013-06-15       Impact factor: 21.198

8.  Personalized versus standardized dosing strategies for the treatment of childhood amblyopia: study protocol for a randomized controlled trial.

Authors:  Merrick J Moseley; Michael P Wallace; David A Stephens; Alistair R Fielder; Laura C Smith; Catherine E Stewart
Journal:  Trials       Date:  2015-04-25       Impact factor: 2.279

9.  A New Dichoptic Training Strategy Leads to Better Cooperation Between the Two Eyes in Amblyopia.

Authors:  Zitian Liu; Zidong Chen; Le Gao; Manli Liu; Yiru Huang; Lei Feng; Junpeng Yuan; Daming Deng; Chang-Bing Huang; Minbin Yu
Journal:  Front Neurosci       Date:  2020-11-26       Impact factor: 4.677

Review 10.  Management of amblyopia in pediatric patients: Current insights.

Authors:  Sagnik Sen; Pallavi Singh; Rohit Saxena
Journal:  Eye (Lond)       Date:  2021-07-07       Impact factor: 3.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.